NCT03340662 is a Phase 1 clinical trial of CC-122 in Healthy Volunteer, sponsored by Celgene.

Who is sponsoring NCT03340662?

NCT03340662 is sponsored by Celgene.

What drugs are being tested in NCT03340662?

Interventions in NCT03340662: CC-122, Itraconazole, Fluvoxamine, Rifampin.

What condition does NCT03340662 study?

NCT03340662 studies Healthy Volunteer.

Is NCT03340662 still recruiting?

NCT03340662 is currently completed. Last updated 16 January 2019.

Last reviewed 2019-01-16 · How we verify

NCT03340662

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122

Completed Phase 1 Last updated 16 January 2019

What this trial tests

Phase 1 trial testing CC-122 in Healthy Volunteer in 81 participants. Completed in 27 January 2018.

Timeline

9 November 2017

Primary endpoint
27 January 2018

27 January 2018

Quick facts

Lead sponsor	Celgene
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	81
Start date	9 November 2017
Primary completion	27 January 2018
Estimated completion	27 January 2018
Sites	1 location across United States

Drugs / interventions tested

CC-122 — full drug profile →
Itraconazole — full drug profile →
Fluvoxamine (FLUVOXAMINE) — full drug profile →
Rifampin — full drug profile →

Conditions studied

Healthy Volunteer — all drugs for Healthy Volunteer →

Sponsor

Celgene — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy Volunteer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 1 open-label 4-part study to evaluate the effect of food, cytochrome P450 inhibition and induction on the pharmacokinetics of CC 122 in healthy adult subjects. Approximately 81 subjects will be enrolled. There will be approximately 24 subjects in Part 1 and approximately 19 subjects in Parts 2, 3, and 4, respectively. Subjects may participate in 1 part only.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.
Xie X, Yu T, Li X, Zhang N, et al · · 2023 · cited 246× · PMID 37669923 · DOI 10.1038/s41392-023-01589-z
Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects.
Ogasawara K, MacGorman K, Liu L, Chen J, et al · · 2019 · cited 5× · PMID 31172535 · DOI 10.1002/jcph.1453

Verify or expand the search:

Other trials of CC-122

Trials testing the same drug.

NCT05688475 — A Rollover Study of CC-122 · Phase 1 · active not recruiting
NCT03834623 — Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma · Phase 2 · completed
NCT03310619 — A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies · Phase 1, PHASE2 · completed
NCT03097016 — A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment · Phase 1 · completed
NCT02859324 — A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcino · Phase 1, PHASE2 · completed

Other recruiting trials for Healthy Volunteer

Currently open trials in the same condition.

NCT06274749 — Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Mask · NA · recruiting
NCT05652478 — Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study · Phase 2 · recruiting
NCT06845176 — Combining Motor Imagery and Tendon Vibration on the Effectiveness of Motor Imagery · NA · recruiting
NCT07439263 — Single Ascending Dose Study of HB2198 in Healthy Participants · Phase 1 · recruiting
NCT07220122 — Impact of Exogenous Ketones on Breathing in Healthy Volunteers · EARLY_PHASE1 · recruiting

Other Celgene trials

Trials by the same sponsor.

NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03340662 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Celgene
Last refreshed: 16 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03340662.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing